Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre and Department of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
Can J Physiol Pharmacol. 2024 Feb 1;102(2):86-104. doi: 10.1139/cjpp-2023-0226. Epub 2023 Sep 25.
Angiotensin II (Ang II) is formed by the action of angiotensin-converting enzyme (ACE) in the renin-angiotensin system. This hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro- and antihypertrophic Ang II receptors (AT1R and AT2R). Ang II is also metabolized by ACE 2 to Ang-(1-7), which elicits the activation of Mas receptors (MasR) for inducing antihypertrophic actions. Since heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, we have reviewed the existing literature to gain some information regarding the roles of AT1R, AT2R, and MasR in both acute and chronic conditions of cardiac hypertrophy. It appears that the activation of AT1R may be involved in the development of adaptive and maladaptive cardiac hypertrophy as well as subsequent heart failure because both ACE inhibitors and AT1R antagonists exert beneficial effects. On the other hand, the activation of both AT2R and MasR may prevent the occurrence of maladaptive cardiac hypertrophy and delay the progression of heart failure, and thus therapy with different activators of these antihypertrophic receptors under chronic pathological stages may prove beneficial. Accordingly, it is suggested that a great deal of effort should be made to develop appropriate activators of both AT2R and MasR for the treatment of heart failure subjects.
血管紧张素 II(Ang II)是由肾素-血管紧张素系统中的血管紧张素转换酶(ACE)作用形成的。已知这种激素可诱导心肌肥厚和心力衰竭,其作用是通过促和抗肥厚血管紧张素 II 受体(AT1R 和 AT2R)的相互作用介导的。Ang II 也被 ACE2 代谢为 Ang-(1-7),它引发 Mas 受体(MasR)的激活,从而引起抗肥厚作用。由于在不同病理生理情况下心力衰竭之前存在适应性和失调性心肌肥厚,我们已经复习了现有文献,以了解 AT1R、AT2R 和 MasR 在急性和慢性心肌肥厚中的作用。似乎 AT1R 的激活可能参与适应性和失调性心肌肥厚以及随后的心力衰竭的发展,因为 ACE 抑制剂和 AT1R 拮抗剂都发挥有益作用。另一方面,AT2R 和 MasR 的激活都可能预防失调性心肌肥厚的发生并延迟心力衰竭的进展,因此在慢性病理阶段下,使用这些抗肥厚受体的不同激活剂进行治疗可能是有益的。因此,建议应做出大量努力来开发适当的 AT2R 和 MasR 激活剂来治疗心力衰竭患者。